title: [Clinical study of prostate cancer: statistical analysis of 107 cases in the past 12 years].
abstract: One hundred and seven patients with prostate cancer were treated at Mie University Hospital during the past 12 years between 1988 and 1999. They were between 53 and 83 years old, with an average age of 70.8 years old. The clinical stage was defined as A, B, C and D in 3 (2.8%), 19 (17.8%), 50 (46.7%) and 35 (32.7%) patients, respectively. At initial diagnosis, the tumor was well, moderately and poorly differentiated adenocarcinoma in 26 (24.3%), 47 (43.9%) and 34 (31.8%) patients, respectively. The median follow-up period was 52.3 months. The overall 1, 3 and 5-year survival rates were 98.0%, 86.8% and 75.2%, respectively. The 5-year survival rates for stage A, B, C and D were 100%, 93.8%, 82.1% and 56.9%, respectively. A significant difference (p = 0.017) in 5-year survival rate was noted between stage C and D. The 5-year survival rate was 100% for well differentiated, 78.0% for moderately differentiated, and 53.2% for poorly differentiated adenocarcinoma. A significant difference (p = 0.0016) in the 5-year survival rate was noted between well differentiated and poorly differentiated adenocarcinoma. According to the therapy, the 5-year survival rate in stage C was 86.2% for the radical prostatectomy group and 84.0% for the endocrine therapy group. There was no significant difference between these 2 treatment groups. Endocrine therapies, classified into maximum androgen blockade (MAB) and endocrine therapy other than MAB were performed for stage D as an initial therapy. Although the prognosis in the patients treated with MAB was better than that with other endocrine therapies, there was no significant difference between these 2 endocrine treatment groups.
authors.affiliation: Department of Urology, Faculty of Medicine, Mie University.
authors.forename: Y
authors.initials: Y
authors.lastname: Umeda
authors.forename: N
authors.initials: N
authors.lastname: Hayashi
authors.forename: K
authors.initials: K
authors.lastname: Ogawa
authors.forename: I
authors.initials: I
authors.lastname: Kuromatsu
authors.forename: O E
authors.initials: OE
authors.lastname: Franco
authors.forename: J
authors.initials: J
authors.lastname: Su
authors.forename: K
authors.initials: K
authors.lastname: Yamakawa
authors.forename: K
authors.initials: K
authors.lastname: Arima
authors.forename: M
authors.initials: M
authors.lastname: Yanagawa
authors.forename: J
authors.initials: J
authors.lastname: Kawamura
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate